NEW YORK--(BUSINESS WIRE)--April 12, 2006--Callisto Pharmaceuticals, Inc. (AMEX:KAL - News; FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has received approval from three of its clinical research sites to advance the clinical trial of its anti-cancer drug candidate Atiprimod to higher dosage levels under the Company’s program to develop the drug as a treatment for the serious blood cancer multiple myeloma.
